Skip to main content

Table 3 Kaplan-meier analysis of time to first moderate/severe exacerbation and to premature withdrawal of patients from the study (ITT Population)

From: Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation

  FP/SAL 250/50 μg SAL 50 μg Hazard Ratio (FP/SAL:SAL)
(N = 314) (N = 325) (95% CI)
Cumulative no. (%) patients with moderate/severe exacerbation 102 (32) 115 (35)  
% probability (95% CI) of moderate/severe exacerbation 45.2 (36.8, 54.5) 47.1 (40.6, 54.2) 0.83 (0.63, 1.09)
Cumulative no. (%) patients withdrawing from the study 98 (31) 119 (37)  
% probability (95% CI) of withdrawal from the study 31.7 (26.7, 37.3) 37.1 (32.0, 42.7) 0.87 (0.67, 1.13)
  1. Hazard ratio and CI are from a Cox proportional hazards model with terms for treatment, country, randomization stratum and baseline severity. CI = confidence interval; FP = fluticasone propionate; ITT = intent-to-treat; SAL = salmeterol.